Sumary of PrEP, the HIV prevention pill, must now be totally free under almost all insurance plans:
- In a move that is expected to prove transformative to the national HIV-prevention effort, the federal government has announced that almost all health insurers must cover the HIV prevention pill, known as PrEP, or pre-exposure prophylaxis, with no cost sharing — including for the drug itself and, crucially, for clinic visits and lab tests.
- The rule says insurers must not charge copays, coinsurance or deductible payments for the quarterly clinic visits and lab tests required to maintain a PrEP prescription.
- ” However, Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, pointed out that many insurers are still not complying with the rule indicating they cannot charge consumers for their Truvada or Descovy prescriptions.
- After a slow start, PrEP began gaining substantial popularity in 2014 as media attention about PrEP’s potential to turn the tide against the U.S. epidemic swelled.
- Descovy, which is associated with improvements in bone density and kidney function tests compared with Truvada, was given the green light by the Food and Drug Administration in 2019. Both drugs are manufactured by Gilead Sciences, which is the dominant player in the HIV treatment market.
- The CDC also released a new estimate in May that during the mid-2010s, the annual rate of new HIV transmissions in the United States remained constant for a few years before declining by about 8 percent between 2015 and 2019, to some 34,800 new cases.
- Siegler, an associate professor at the Rollins School of Public Health at Emory University, and his colleagues found that states that expanded their Medicaid programs under the Affordable Care Act and those that offered programs to offset the costs of PrEP benefited from greater use of the prevention modality.